DVL1 and non-small cell lung carcinoma: Therefore, our results suggest that Dvl1 is a potential therapeutic target for NSCLC and that miR-214 plays an inhibitory role in Dvl1-mediated activation of Wnt/β-catenin signalling in NSCLC cells, which may affect the progression of NSCLC.